As the incidence and mortality rates of pancreatic cancer continue to rise, it is projected to become the second leading cause of cancer-related deaths in the United States by 2030. Pancreatic cancer has a poor prognosis, with a mortality rate very close to its incidence rate, largely due to the lack of early detection methods and effective therapeutic regimens. In response to this urgent clinical need, our team published this research identifying a novel fetal-onco protein, carcinoembryonic antigen-related cell adhesion molecule 7 (CEACAM7), which is expressed only in pancreatic cancer, especially in the early stages.